Up To 50 SAR OFF Your First Order Use Code : APP50 | Get Free Delivery With No Minimum Order

Frequently bought together
RESOVA 10/MG TAB 30/TAB
- Sku : I-018459
Key features
Resova 10mg Film-coated tablet 30 Tabl is a film-coated tablet containing rosuvastatin 10 mg as the active ingredient. It works by inhibiting HMG-CoA reductase in the liver, reducing cholesterol synthesis and lowering circulating LDL cholesterol. It is indicated for the treatment of elevated LDL cholesterol and other lipid disorders and for reducing the risk of atherosclerotic cardiovascular events. Available by prescription as film-coated tablets in a pack of 30.- Brand: RESOVA
- Active Ingredient: ROSUVASTATIN 10mg
- Strength: 10mg
- Dosage Form: Film-coated tablet
- Pack Size: 30 Tablets
- Route: Oral use
- Prescription Status: Prescription
- Therapeutic Class: Lipid Modifying
- Pharmacological Group: Statins
- Drug Class: HMG-CoA Reductase Inhibitor (Statin) - Synthetic, hydrophilic statin
- Manufacturer: Jazeera Pharmaceutical Industries (JPI)
- Country of Origin: Saudi Arabia
- SFDA Registration No.: 0501221559
- Shelf Life: 24 months
- Storage: store below 30°c
- Lipid Target: Both: Triglycerides & LDL
Frequently bought together
Dosage & Administration
Dosing by Condition
Primary hypercholesterolemia/mixed dyslipidemia: start 5-10 mg PO once daily (some patients may start 10-20 mg based on LDL-C reduction needed), usual 10-20 mg, max 40 mg daily. Hypertriglyceridemia: 5-10 mg daily initially, titrate; max 40 mg daily. Homozygous familial hypercholesterolemia: start 20 mg once daily, max 40 mg once daily. Primary prevention/risk reduction: 10-20 mg once daily (dose individualized to risk and LDL-C goal).
Initial Dose
The usual starting dose is 10 to 20 mg once daily.
Maintenance Dose
10-20mg once daily
Maximum Dose
40mg once daily.
Children's Dosage
Heterozygous Familial Hypercholesterolemia (HeFH): 5-10mg daily for ages 8 to <10 years; 5-20mg daily for ages 10 to 17 years. Homozygous Familial Hypercholesterolemia (HoFH): 20mg daily for ages 7 to 17 years.
Dose Adjustment Notes
Assess lipids and titrate at intervals of about 4 weeks; consider lower starting dose (e.g., 5 mg) in patients with higher exposure risk (e.g., Asian ancestry) and in those with renal impairment; 40 mg is reserved only for patients not at goal on 20 mg with careful monitoring; adjust/limit dose with interacting drugs (e.g., avoid with cyclosporine; limit dose with certain HIV protease inhibitors).
How to Take
Swallow tablet whole with water. Can be taken at any time of day, with or without food. Take at the same time each day for consistency.
Safety & Warnings
Contraindications
Contraindicated in: hypersensitivity to rosuvastatin/excipients; active liver disease including unexplained persistent elevations of serum transaminases; pregnancy; breastfeeding; concomitant use with cyclosporine.
Age Restriction
Pediatric use information for patients 7 to 17 years of age is approved for AstraZeneca’s CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
Drug Interactions
Drug Interactions
Clinically important interactions include: cyclosporine (contraindicated/avoid); gemfibrozil (avoid if possible; increases exposure and myopathy risk); protease inhibitors (e.g., atazanavir/ritonavir, lopinavir/ritonavir-dose limit/avoid high doses); warfarin (may increase INR-monitor); aluminum/magnesium antacids (reduce rosuvastatin absorption-separate dosing); niacin and fibrates (incl. fenofibrate) (additive myopathy risk); colchicine (myopathy risk); fusidic acid (avoid/temporarily stop statin due to rhabdomyolysis risk).
Interaction Severity
MAJOR: Cyclosporine (markedly increases rosuvastatin exposure-avoid/contraindicated per many labels); Gemfibrozil (increases exposure and myopathy risk-avoid). MODERATE: Warfarin (may increase INR-monitor), HIV protease inhibitors (e.g., lopinavir/ritonavir, atazanavir/ritonavir-limit rosuvastatin dose), other fibrates (e.g., fenofibrate) and niacin (additive myopathy risk-use caution/monitor), colchicine (myopathy risk-monitor), fusidic acid (serious myopathy risk-avoid combination/temporarily stop statin). MINOR: Aluminum/magnesium antacids (reduce absorption-separate by ~2 hours).
Food Interaction
No clinically meaningful food restriction; may be taken with or without food.
Special Populations
Pregnancy
Contraindicated
Breastfeeding
Contraindicated
Children
Heterozygous Familial Hypercholesterolemia (HeFH): 5-10mg daily for ages 8 to <10 years; 5-20mg daily for ages 10 to 17 years. Homozygous Familial Hypercholesterolemia (HoFH): 20mg daily for ages 7 to 17 years.
Kidney Impairment
Severe renal impairment (CrCl <30 mL/min/1.73 m², not on hemodialysis): start 5 mg once daily and do not exceed 10 mg once daily; mild-moderate impairment: no adjustment; hemodialysis: start 5 mg once daily and do not exceed 10 mg once daily.
Storage & Patient Advice
Missed Dose
Take the missed dose as soon as remembered the same day; if it is close to the next dose, skip the missed dose and resume the regular schedule-do not double doses.
Patient Counseling
Take once daily at the same time, with or without food; continue long-term alongside diet/exercise. Report unexplained muscle pain/weakness or dark urine promptly. Avoid use in pregnancy; inform provider if pregnant/planning pregnancy or breastfeeding. Limit excessive alcohol and report symptoms of liver injury. Tell clinicians about all medicines (notably cyclosporine, gemfibrozil, warfarin, HIV antivirals, and antacids-separate antacids by ~2 hours). Attend follow-up lipid tests and any symptom-triggered labs.
Pharmacology
Metabolism
Minimal metabolism; ~10% is metabolized (mainly by CYP2C9, with minor CYP2C19), and most circulating drug is unchanged rosuvastatin.
Protein Binding
Approximately 88% protein bound (primarily to albumin).
Product Information
Available Dosage Forms
Film-coated tablet
Composition per Dose
Each film-coated tablet: 10mg rosuvastatin (as rosuvastatin calcium)
Generic Availability
Yes
Lipid Target
Both
Legal Disclaimer - Al Mujtama Pharmacy
The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.
Al Mujtama Pharmacy assumes no legal or medical liability for:
- Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
- Any discrepancy between the information provided and the product's package insert or SFDA guidelines
- Any misuse of medication resulting from personal interpretation of the content displayed
Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.
By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.
Your health is a trust - always consult your doctor first.
-1744229570.gif)











